90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 891-895

  Ria, Roberto ^a   Musto, Pellegrino ^b   Reale, Antonia ^a   Guariglia, Roberto ^b   Iodice, Giuseppe ^a   Dammacco, Franco ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

90Y ibritumomab tiuxetan; Autologous stem cell transplantation; Consolidation therapy; Non Hodgkin lymphoma

Indexed keywords

ERYTHROPOIETIN; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; MAINTENANCE THERAPY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 79958093093     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084376     Document Type: Article

References (20)

1. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:497-506.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
3. Gao G, Liang X, Jiang J, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol. 2010;49:3-12.
4. Ahmed S, Winter JN, Gordon LI, Evens AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma. 2010;51:1163-1177.
5. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269. (Pubitemid 34831524)
6. Dillman RO. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Curr Hematol Rep. 2003;2:30-37.
7. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs. 2007;67:333-350. (Pubitemid 46425549)
8. 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res. 2005;11(19, suppl)7146s-7150s.
9. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545-3557.
10. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)
11. Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer. 2010;116(4, suppl):1126-1133.
12. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122-135.
13. 131I-tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
14. Morschhauser F, Dreyling F, Rohatiner A, Hagemeister F, Delaloye AB. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist. 2009;14(suppl 2):17-29.
15. Hamlin PA, Moskowitz CH, Wegner B, et al. Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL [abstract]. Ann Oncol. 2008;19(suppl 4):100.
16. Emmanouilides C. Radioimmunotherapy for non-Hodgkin lymphoma: historical perspective and current status. J Clin Exp Hematop. 2007;47:43-60.
17. Brugger W, Hirsch J, Grünebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004;15:1691-1698. (Pubitemid 39562612)
18. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:5213-5218.
19. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573. (Pubitemid 46291820)
20. 90Y-ibritumomab tiuxetan) [abstract]. Ann Oncol. 2008;19 (suppl 4):iv173.